FDA approves Cobas EZH2 Mutation Test as CDx

July 7, 2020—The Food and Drug Administration approved the Roche Cobas EZH2 Mutation Test as a companion diagnostic for Tazverik (tazemetostat), developed by Epizyme. This molecular test detects abnormalities in the *EZH2*, or enhancer of zeste homolog 2, gene in patients with follicular lymphoma. It is expected to be available in the Unites States later this year.